Navigation Links
Pfizer And Epocrates Partner To Give Healthcare Providers Access To Medical Information Specialists For Medication Questions
Date:6/2/2010

NEW YORK, June 2 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) and Epocrates, Inc., today announced a collaboration to give healthcare providers (HCPs) mobile access to the Pfizer Medical Information Group to obtain scientific answers to their product questions or to report an adverse event.  For the first time, clinicians can make direct contact through the Epocrates drug reference app on their iPhone® device to pharmaceutical manufacturers and immediately apply findings to patient care.  Pfizer is enabling easy, direct access to its Medical Information services, via the Epocrates channel, in an effort to enhance the safe and effective use of its medicines, and help improve the quality of patient care.

(Photo: http://www.newscom.com/cgi-bin/prnh/20100602/NY14104-a)

(Photo: http://www.newscom.com/cgi-bin/prnh/20100602/NY14104-b)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100602/NY14104LOGO-c)

"Contact Pfizer" is now a feature available in the Epocrates drug profiles of approximately 40 Pfizer products.  By providing easy access directly to the manufacturer, this feature provides Epocrates' users the option for immediate phone access to Pfizer Medical Information specialists to obtain scientific information about the company's medications and report adverse reactions.  Additionally, healthcare providers will soon have the option to email Pfizer Medical Information for select Pfizer products.

"Healthcare providers have told us they would like direct access to our medical specialists so they can communicate with us in an open, unbiased manner," said Freda C. Lewis-Hall, M.D., FAPA, senior vice president and chief medical officer at Pfizer.  "They expect rapid and tailored scientific responses to their medical questions about our drugs.  Our hope is that the introduction of this new and innovative feature on Epocrates enables doctors and other providers to enhance the care they can provide to their patients using Pfizer medicines."

According to Manhattan Research, 72 percent of doctors currently own smartphones; a number that is expected to increase to four out of five doctors by 2012.  One of their primary uses is to look up prescription drug information at the point of patient care.  Epocrates is the leader in the mobile drug reference and decision support space.  More than 950,000 healthcare professionals, including more than 40 percent of U.S. physicians, actively use Epocrates products, commonly on mobile devices such as iPhone, BlackBerry®, Android™ and Palm®.  

"Epocrates is committed to providing healthcare providers with the resources they need to make the best clinical decisions for their patients at the point of care," said Rose Crane, chief executive officer at Epocrates.  "It is at this 'moment of truth' physicians may have a question only the manufacturer can answer. We are the only company in a position to facilitate that direct link, and significantly advance communication between a manufacturer such as Pfizer and our strong network of HCPs."

The "Contact Manufacturer" feature is initially available to iPhone and iPod touch® device users of the Epocrates application, which includes more than 150,000, or nearly 25 percent, of U.S. doctors.  Epocrates will work to expand the feature to other mobile platforms as its impact on patient care is demonstrated.  As the first company to utilize "Contact Manufacturer," Pfizer helped support the concept and design to ensure the tool was developed to optimally manage physician queries.

About Epocrates, Inc.

Epocrates is a leading provider of clinical information and decision support tools to healthcare professionals.  Epocrates currently has more than 950,000 healthcare professionals, including 40 percent of U.S. physicians and medical students, in its active network.  The company's clinical products and services enable healthcare professionals to make more informed medical decisions, reduce medical errors and practice more efficiently. For more information about Epocrates, please visit www.epocrates.com/company.    

Pfizer Inc:  Working together for a healthier world™

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.


'/>"/>
SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. MannKind Addresses Pfizers Announcement Regarding Exubera
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
11. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
(Date:6/24/2016)... , June 24, 2016  Consumers have ... and regulators/payers have placed more emphasis on patient ... patient support programs in the pharmaceutical industry have ... medications. Consequently, pharmaceutical companies are focusing on becoming ... are providing products and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
Breaking Medicine News(10 mins):